Continuous clindamycin infusion, an innovative approach to treating bone and joint infections

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 1, 2010, Pages 88-92

  Zeller, Valérie ^a   Dzeing Ella, Arnaud ^a   Kitzis, Marie Dominique ^b   Ziza, Jean Marc ^a   Mamoudy, Patrick ^a   Desplaces, Nicole ^a  

^a GROUPE HOSPITALIER DIACONESSES CROIX SAINT SIMON   (France)

^b SAINT JOSEPH HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; RIFAMPICIN;

ADULT; AGED; ARTICLE; BONE INFECTION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INFECTIOUS ARTHRITIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BONE DISEASES, INFECTIOUS; CLINDAMYCIN; COHORT STUDIES; DRUG INTERACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; JOINT DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIFAMPIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 73849101373     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01081-09     Document Type: Article

References (30)

1. Ambrose, P. G., S. M. Bhavnani, C. M. Rubino, A. Louie, T. Gumbo, A. Forrest, and G. L. Drusano. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44: 79-86.
2. Aucoin, P., R. R. Beckner, and N. M. Gantz. 1982. Clindamycin-induced cardiac arrest. South. Med. J. 75:768.
3. Bernard, L., L. El-Hajj, B. Pron, A. Lotthé, V. Gleizes, F. Signoret, P. Denormandie, J. L. Gaillard, and C. Perrone. 2001. Outpatient parenteral antimicrobial therapy (OPAT) for the treatment of osteomyelitis: evaluation of efficacy, tolerance and cost. J. Clin. Pharm. Ther. 26:445-451.
4. Brandi, L. S., M. Grana, and M. Carmellini. 1983. Cardiac arrest induced by intravenous administration of clindamycin phosphate. Description of a clinical case. Minerva Anestesiol. 49:535-537.
5. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antimicrobial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
6. Dall, L., M. Keilhofner, B. Herndon, W. Barnes, and J. Lane. 1990. Clindamycin effect on glycocalyx production in experimental viridans streptococcal endocarditis. J. Infect. Dis. 161:1221-1224.
7. Dornbusch, K., A. Carlström, H. Hugo, and A. Lidströlm. 1977. Antibacterial activity of clindamycin and lincomycin in human bone. J. Antimicrob. Chemother. 3:153-160.
8. Dripps, R. D., A. Lamont, and J. E. Eckenhoff. 1961. The role of anaesthesia in surgical mortality. JAMA 178:261-266.
9. Duckworth, C., J. F. Fisher, S. A. Carter, C. L. Newman, C. Cogburn, and R. R. Nesbit. 1993. Tissue penetration of clindamycin in diabetic foot infections. J. Antimicrob. Chemother. 31:581-584.
10. El Samad, Y., E. Havet, H. Bentayeb, B. Olory, B. Canarelli, J. F. Lardanchet, Y. Douadi, F. Rousseau, F. X. Lescure, P. Mertl, F. Eb, and J. L. Schmit. 2008. Treatment of osteoarticular infections with clindamycin in adults. Med. Mal. Infect. 38:465-470.
11. Feigin, R. D., L. K. Pickering, D. Anderson, R. E. Keeney, and P. G. Shakleford. 1975. Clindamycin treatment of osteomyelitis and septic arthritis in children. Pediatrics 55:213-223.
12. Geddes, A. M., N. S. Dwyer, A. P. Ball, and R. S. Amos. 1977. Clindamycin in bone and joint infections. J. Antimicrob. Chemother. 3:501-507.
13. Gisby, J., A. S. Beale, J. E. Bryant, and C. D. Toseland. 1994. Staphylococcus osteomyelitis - a comparison of co-amoxiclav with clindamycin and flucloxacillin in an experimental rat model. J. Antimicrob. Chemother. 34:755-764.
14. Kasiakou, S. K., G. J. Sermaides, A. Michalopoulos, E. S. Soteriades, and M. E. Falagas. 2005. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect. Dis. 5:581-589.
15. Lazzarini, L., B. A. Lipsky, and J. T. Mader. 2005. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int. J. Infect. Dis. 9:127-138.
16. Mader, J. T., K. Adams, and L. Morrison. 1989. Comparative evaluation of cefazolin and clindamycin in the treatment of experimental Staphylococcus aureus osteomyelitis in rabbits. Antimicrob. Agents Chemother. 33:1760-1764.
17. Mansur, J. M., P. W. Abramowitz, S. A. Lerner, R. B. Smith, and R. J. Townsend. 1985. Stability and cost analysis of clindamycin-gentamicin admixtures given every eight hours. Am. J. Hosp. Pharm. 42:332-335.
18. Mayberry-Carson, K. J., W. R. Mayberry, B. K. Tober-Meyer, J. W. Costerton, and D. W. Lambe. 1986. An electron microscopic study of the effect of clindamycin on adherence of Staphylococcus aureus to bone surface. Microbios 45:21-32.
19. Mayberry-Carson, K. J., B. Tober-Meyer, D. W. Lambe, and J. W. Costerton. 1986. An electron microscopic study of the effect of clindamycin therapy on bacterial adherence and glycocalyx formation in experimental Staphylococcus aureus osteomyelitis. Microbios 48:189-206.
20. Niemi, M., J. T. Backman, M. F. Fromm, P. J. Neuvonen, and K. T. Kivistö. 2003. Pharmacokinetic interactions with rifampin: clinical relevance. Clin. Pharmacokinet. 42:819-850.
21. Panzer, J. D., D. C. Brown, W. L. Epstein, R. L. Lipson, H. W. Mahaffey, and W. H. Atkinson. 1972. Clindamycin levels in various body tissues and fluids. J. Clin. Pharmacol. 12:259-262.
22. Plott, M. A., and H. Roth. 1970. Penetration of clindamycin into synovial fluid. Clin. Pharmacol. Ther. 11:577-580.
23. Schurman, D. J., B. L. Johnson, G. Finerman, and H. C. Amstutz. 1975. Antibiotic bone penetration. Concentrations of methicillin and clindamycin phosphate in human bone taken during total hip replacement. Clin. Orthop. Rel. Res. 111:142-146.
24. Sousa, M., A. Pozniak, and M. Boffito. 2008. Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs. J. Antimicrob. Chemother. 62:872-878.
25. Steigbigel, N. H. 2000. Macrolides and clindamycin, p. 366-382. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 5th ed. Churchill Livingstone, Philadelphia, PA.
26. Stengel, D., K. Bauwens, J. Sehouli, A. Ekkernkamp, and F. Porzsolt. 2001. Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. Lancet Infect. Dis. 1:175-188.
27. Summersgill, J. T., L. G. Schupp, and M. J. Raff. 1982. Comparative penetration of metronidazole, clindamycin, chloramphenicol, cefoxitin, ticarcillin, and moxalactam into bone. Antimicrob. Agents Chemother. 21:601-603.
28. Tice, A. D., S. J. Rehm, J. R. Dalovisio, J. S. Bradley, L. P. Martinelli, D. R. Graham, R. B. Gainer, M. J. Kunkel, R. W. Yancey, and D. N. Williams. 2004. Practice guidelines for outpatient parenteral antimicrobial therapy. Clin. Infect. Dis. 38:1651-1672.
29. Weinstein, M. P., C. W. Stratton, H. B. Hawley, A. Ackley, and L. B. Reller. 1987. Multicenter collaborative evaluation of standardized serum bactericidal test as a predictor of therapeutic efficacy in acute and chronic osteomyelitis. Am. J. Med. 83:218-222.
30. Zeller, V., F. Durand, M. D. Kitzis, L. Lhotellier, J. M. Ziza, P. Mamoudy, and N. Desplaces. 2009. Prolonged continuous intravenous cefazolin to treat bone and joint infections: feasibility, tolerance, efficacy, serum and bone concentrations. Antimicrob. Agents Chemother. 53:883-887.